



FOR IMMEDIATE RELEASE

Contacts: Jesse Bailey,
Chief Development Officer,
Jesse.bailey@targetals.org
(646) 592-2541

Target ALS Will Provide ALS Scientists Access to Critical Tool to Study C9orf72 Biology

New York City— June 21, 2018- Target ALS announced today that it will make the poly(GP) monoclonal antibody available to the ALS research community worldwide as part of the Foundation’s commitment to creating shared scientific resources to fast track ALS drug development.

Recent scientific breakthroughs have revealed that Hexanucleotide (GGGGCC) expansion in the *C9ORF72* gene is the most common genetic cause of both ALS and frontotemporal degeneration, commonly known as FTD. This new research tool, the poly(GP) monoclonal antibody, detects poly(GP), one of several dipeptide repeat (DPR) proteins produced from expanded GGGGCC repeats in the *C9ORF72* gene.

“At Target ALS, one of our goal is to provide scientists worldwide with the tools and resources they need to develop effective treatments for ALS. The new poly(GP) antibody is the first in a series of research tools that we are creating to intensify and accelerate drug discovery and development work on C9orf72 ALS,” said Target ALS CEO Manish Raisinghani.

Target ALS generated the poly(GP) monoclonal antibody from two hybridoma clones. Investigators worldwide can access the more immunoreactive of the two purified monoclonal antibodies (TALS 828.179) by contacting Target ALS at manish.raisinghani@targetals.org. In addition, the two hybridoma clones have been deposited at the Developmental Studies Hybridoma Bank (DHSB). The supernatant from both clones (TALS 828.179 and TALS 828.66) work similarly in validation assays and can be accessed by contacting DHSB directly at <http://dshb.biology.uiowa.edu>.

Additional information on this antibody and all Target ALS Core Facilities can be found at http://www.targetals.org/about-us/core_facilities.html.

About Target ALS

Founded by Daniel L. Doctoroff, Target ALS is a pioneering medical research foundation whose goal is to accelerate the discovery and development of effective treatments for patients with ALS. Learn more at www.targetals.org.